Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication LYRICA is indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: • Neuropathic pain associated with diabetic…
Pregabalin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Pregabalin | DRUG | - |
| Alprazolam | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Male or female outpatients 18 years of age or older who score 12 points or more on the Dental Anxiety Scale at screening and baseline evaluations and have a scheduled appointment for an elective dental procedure. Exclusion Criteria: * Current diagnosis of any of the DSM-IV a...
Pregabalin is being studied as an investigational treatment for dental anxiety, the fear or distress patients experience before a dental procedure. Viatris Inc. (VTRS) has evaluated it in a Phase 2 trial in adults with anxiety prior to dental treatment. It is not established as a routine treatment for this indication.
Pregabalin targets several calcium channel subunits, including CACNA1H, CACNA2D1, CACNA1C, CACNA2D3, CACNA1S, and CACNA2D2. It acts as a modulator of these targets. This calcium channel activity is the basis for its pharmacological effects in the conditions where it is studied.
Viatris Inc. (ticker VTRS) is the developer associated with this Pregabalin program for dental anxiety. The company is listed as the sponsor of the Phase 2 clinical trial evaluating the drug in this indication.
Pregabalin is in Phase 2 development for dental anxiety. The program has one completed Phase 2 trial, and no active trials are currently listed. It remains an investigational use and is not approved for dental anxiety.
Pregabalin has been tested in the Phase 2 trial NCT00245609, titled Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure. The completed trial enrolled 90 adults across Germany and the United Kingdom and used a randomized, double-blind design.